Affinage

Showing MZF1 — MZF-1 is a alias.

MZF1

Myeloid zinc finger 1 · UniProt P28698

Length
734 aa
Mass
82.1 kDa
Annotated
2026-06-10
78 papers in source corpus 50 papers cited in narrative 50 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 9/9 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MZF1 (myeloid zinc finger 1) is a Krüppel-family C2H2 zinc finger transcription factor that uses two independent DNA-binding domains—zinc fingers 1–4 and 5–13, each recognizing a distinct G-rich consensus—to regulate target genes from G-rich promoter elements (PMID:8114711). It functions as a context-dependent bifunctional regulator, repressing transcription in non-hematopoietic cells while activating it in hematopoietic cells, and it directly controls hematopoietic differentiation genes including CD34 and c-myb (PMID:7579328, PMID:7565760). Genetic loss of Mzf1 in mice causes lethal myeloid neoplasia and autonomous progenitor proliferation, establishing it as a hematopoietic growth/tumor suppressor, whereas aberrant overexpression confers anchorage-independent growth and tumorigenicity in fibroblasts and survival signaling in myeloid cells (PMID:7627970, PMID:11445537). Across cancers MZF1 directly transactivates a broad set of pro-tumorigenic targets—c-MYC, PKCα, FOXM1, p55PIK, and cathepsin B/L—to drive proliferation, invasion, EMT, and matrix degradation (PMID:24793789, PMID:26010542, PMID:25425970, PMID:29510992), yet it also acts as a tumor suppressor by activating ferroportin and SMAD4 and by repressing IGF-IR, illustrating strict context dependence (PMID:25284586, PMID:27922669, PMID:25884514). Its protein–protein interactions are organized by an N-terminal SCAN domain that forms a domain-swapped homodimer and supports heterodimerization with partners such as RAZ1, and by a separate acidic region that mediates direct heterodimerization with Elk-1 to assemble DNA-binding transcription complexes on the PKCα promoter (PMID:16950398, PMID:10777584, PMID:26010542). MZF1 also nucleates cofactor complexes with CHD7 to drive oncogenic-Ras-induced p16INK4A transcription and senescence, and with SETD8 on the WNT5A promoter (PMID:34773072, PMID:35350980). Its activity and abundance are tightly post-translationally controlled: CK2 phosphorylates MZF1 at serine 27 to stabilize it and promote N-cadherin-driven EMT, the CHIP/STUB1 ubiquitin ligase represses its nuclear DNA-binding activity, and SUMO1 modification organizes MZF1 into intranuclear nuclear bodies (MZF1-NBs) linked to a stress-response and RNA-binding interactome (PMID:29540671, PMID:29510992, PMID:39954358). MZF1 mRNA itself is a node of RNA modification control, being stabilized by FTO-mediated m6A demethylation and by NSUN2/ALYREF-mediated m5C reading (PMID:29842885, PMID:33533172, PMID:42249105). Beyond cancer, MZF1 transcriptionally regulates TRPV1 in dorsal root ganglion neurons to drive neuropathic pain and engages glycolytic and proline-synthesis programs (HK2, PGK1, ALDH18A1, PYCR1) in neuroblastoma, where a uORF-encoded micropeptide modulates its upstream activator YY1 (PMID:31582966, PMID:32042322, PMID:31592410).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1994 High

    Defining the DNA-recognition logic of MZF1 was the first mechanistic question: the work established that MZF1 has two independent zinc-finger DNA-binding modules each recognizing a distinct G-rich consensus, explaining how one factor can engage diverse promoters.

    Evidence SELEX site selection and EMSA with purified recombinant zinc-finger domains

    PMID:8114711

    Open questions at the time
    • Did not establish which target genes the two consensus motifs map to in vivo
    • No structural model of finger-DNA contacts
  2. 1995 High

    These studies resolved whether MZF1 activates or represses, showing it is bifunctional in a cell-type-dependent manner and directly controls hematopoietic genes CD34 and c-myb, framing MZF1 as a regulator of myeloid differentiation.

    Evidence GAL4-fusion reporter assays, EMSA, promoter mutagenesis, and ES-cell differentiation readouts in hematopoietic vs non-hematopoietic lines

    PMID:7565760 PMID:7579328

    Open questions at the time
    • Molecular basis of the activator-vs-repressor switch (cofactor identity) not defined
    • Did not identify cell-type-specific partners driving the switch
  3. 1995 Medium

    Gain-of-function experiments addressed whether dysregulated MZF1 is oncogenic, demonstrating that aberrant overexpression transforms fibroblasts and promotes tumor formation and that it blocks IL-3-withdrawal apoptosis, linking MZF1 to proliferation and survival.

    Evidence Retroviral overexpression with anchorage-independence, xenograft/syngeneic tumor formation, and cytokine-withdrawal apoptosis assays

    PMID:7627970 PMID:8667641 PMID:9593266

    Open questions at the time
    • Transforming target genes not identified in these models
    • Survival mechanism beyond association with Bcl-2 not delineated
  4. 2001 High

    A definitive loss-of-function test asked whether endogenous Mzf1 restrains hematopoietic growth in vivo, showing knockout mice develop lethal myeloid neoplasia and autonomous progenitor proliferation—establishing MZF1 as a hematopoietic tumor/growth suppressor in apparent paradox with its oncogenic overexpression phenotypes.

    Evidence Mzf1 knockout mice with histopathology and hematopoietic colony/LTC-IC assays

    PMID:11445537

    Open questions at the time
    • Direct target genes mediating the suppressor phenotype not identified
    • Reconciliation of suppressor vs oncogene roles at molecular level unresolved
  5. 2000 High

    To explain how MZF1 forms higher-order complexes, the SCAN/LeR domain was identified as the protein-interaction module mediating homodimerization and heterodimerization with the SCAN-related partner RAZ1.

    Evidence Bone-marrow two-hybrid screen, co-IP, and yeast two-hybrid truncation mapping

    PMID:10777584

    Open questions at the time
    • Functional consequence of RAZ1 heterodimerization on transcription not tested
    • Full repertoire of SCAN partners unknown
  6. 2006 High

    Structural work answered how the SCAN domain mediates dimerization, revealing a domain-swapped homodimer with a helix-3 interface and a measurable affinity, providing the molecular basis for SCAN-mediated interactions.

    Evidence NMR structure determination, GST pull-down, and Kd measurement by fluorescence polarization

    PMID:16950398

    Open questions at the time
    • Structure of heterodimeric SCAN complexes not solved
    • No structure of full-length MZF1 with DNA
  7. 2005 Medium

    Identification of direct promoter targets in non-hematopoietic contexts (N-cadherin, ERV-9 LTR, PKCα, ERCC1) and partners (NF-Y, GATA-2, Sp1, LDOC1) showed MZF1 assembles cell-type-specific enhancer complexes and can both activate and repress distinct targets.

    Evidence EMSA/supershift, promoter-reporter mutagenesis, antisense/co-transfection, and co-IP across osteoblast, K562, hepatoma, and apoptosis models

    PMID:15541732 PMID:15670815 PMID:16105833 PMID:16297876 PMID:16426580

    Open questions at the time
    • Whether MZF1 directly recruits the named partners or co-occupies independently is often not separated
    • In vivo relevance of individual targets to physiology not established
  8. 2014 Medium

    A large body of cancer studies mapped MZF1 into specific oncogenic and tumor-suppressive transcriptional circuits, defining context-dependent direct targets (c-MYC, FOXM1, p55PIK, ferroportin, SMAD4, IGF-IR, PRAME, CK17) and upstream activators (LKB1 loss, OPN/integrin, NKX2-1, TGF-β1/ERK).

    Evidence ChIP, promoter-reporter assays, bidirectional knockdown/overexpression, pharmacologic pathway inhibition, and xenograft/metastasis models across multiple tumor types

    PMID:23509792 PMID:24793789 PMID:25284586 PMID:25425970 PMID:25531323 PMID:25884514 PMID:25899830 PMID:27922669 PMID:28634046 PMID:28703907

    Open questions at the time
    • What determines oncogene vs suppressor target selection in a given tissue is not resolved
    • Most targets are demonstrated in a single lab/model
  9. 2025 Medium

    A second mechanistic layer was opened by showing MZF1 is itself heavily post-translationally and post-transcriptionally regulated: CK2 phosphorylation at S27 stabilizes it, CHIP/STUB1 represses its nuclear DNA-binding, SUMO1 organizes it into MZF1 nuclear bodies, and m6A (FTO) and m5C (NSUN2/ALYREF) marks tune its mRNA stability.

    Evidence Phosphorylation/co-IP assays, ubiquitin-ligase functional screens, SUMOylation and live-cell imaging with interactome proteomics, and MeRIP/RIP/CLIP/mRNA-stability assays with in vivo models

    PMID:29510992 PMID:29540671 PMID:29842885 PMID:33533172 PMID:39954358 PMID:41201047 PMID:42249105 PMID:48

    Open questions at the time
    • Functional output of MZF1-NBs and SUMOylation not mechanistically tied to transcriptional programs
    • How these inputs are integrated to set net MZF1 activity is undefined
  10. 2021 High

    Cofactor-based mechanisms clarified how MZF1 controls senescence and metabolic programs: it recruits CHD7 to the p16INK4A promoter to enact oncogenic-Ras senescence, cooperates with SETD8 on WNT5A, and drives glycolytic/proline-synthesis genes regulated by a uORF-encoded micropeptide acting on its activator YY1.

    Evidence Co-IP cofactor identification, ChIP, senescence assays, Seahorse/amino-acid profiling, peptide pull-down, and xenografts

    PMID:31592410 PMID:32042322 PMID:34773072 PMID:35350980

    Open questions at the time
    • Generality of CHD7/SETD8 recruitment across other targets unknown
    • How chromatin cofactor choice is governed is unresolved
  11. 2019 Medium

    MZF1 was shown to operate in non-cancer tissue contexts—neuropathic pain via TRPV1 in DRG neurons, glomerular inflammation/fibrosis via RGC-32 and WNT5A, mTOR regulation, and cardiac remodeling via HTRA1—broadening its physiological reach beyond hematopoiesis and tumors.

    Evidence DRG microinjection with behavioral assays, ChIP/reporter assays, EMSA/DNA pulldown for allelic Mtor sites, and in vivo nephritis, fibrosis, and heart-failure models

    PMID:31184423 PMID:31548308 PMID:31582966 PMID:42249105

    Open questions at the time
    • Tissue-specific cofactors enabling these distinct programs not identified
    • Most physiological roles rest on single studies

Open questions

Synthesis pass · forward-looking unresolved questions
  • The central unresolved question is what molecular determinant switches MZF1 between tumor-suppressor and oncogene roles and selects its activator vs repressor mode on a given promoter.
  • No unifying model linking partner identity, post-translational state, and target selection
  • No genome-wide occupancy comparison across hematopoietic vs non-hematopoietic contexts in the corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5
Localization
GO:0005634 nucleus 2 GO:0005654 nucleoplasm 1
Pathway
R-HSA-74160 Gene expression (Transcription) 7 R-HSA-1643685 Disease 5 R-HSA-8953854 Metabolism of RNA 4
Partners
CDK4CHD7CK2ELK-1RAZ1SETD8STUB1YY1
Complex memberships
MZF1 SCAN domain-swapped homodimerMZF1 nuclear bodies (MZF1-NBs)MZF1/Elk-1 heterodimer

Evidence

Reading pass · 50 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1994 MZF1 contains two independent DNA-binding domains (zinc fingers 1–4 and zinc fingers 5–13), each of which binds distinct but G-rich consensus sequences (1–4: 5'-AGTGGGGA-3'; 5–13: 5'-CGGGnGAGGGGGAA-3') as determined by affinity selection from degenerate oligonucleotide libraries followed by gel-shift assays with purified recombinant protein. Recombinant protein purification, SELEX (gel shift + PCR amplification), electrophoretic mobility shift assay (EMSA) Molecular and cellular biology High 8114711
1995 MZF1 functions as a bifunctional transcriptional regulator: it represses transcription in non-hematopoietic cell lines (NIH 3T3, 293) and activates transcription in hematopoietic cell lines (K562, Jurkat) when fused to the GAL4 DNA-binding domain, and it directly binds MZF1 consensus sites in the CD34 promoter to regulate CD34 expression in a cell-type-specific manner. GAL4 fusion co-transfection/CAT reporter assay, luciferase reporter assay, EMSA with recombinant MZF1 on CD34 promoter oligonucleotides, site-directed mutation of MZF1 binding sites Blood High 7579328
1995 Constitutive MZF1 overexpression in embryonic stem cells inhibits hematopoietic commitment and erythromyeloid colony formation, and suppresses CD34 and c-myb promoter activity by directly binding MZF1 consensus sites in their 5'-flanking regions. Retroviral/constitutive transfection into embryonic stem cells, CAT reporter assay, EMSA with recombinant MZF1 on CD34 and c-myb promoters Molecular and cellular biology High 7565760
1995 Retroviral overexpression of MZF1 in NIH 3T3 fibroblasts causes loss of contact inhibition, loss of substrate dependence, accelerated cell cycling, and aggressive tumor formation in athymic mice, demonstrating oncogenic activity when MZF1 is aberrantly expressed. Retroviral transduction of NIH 3T3 cells, soft-agar/anchorage-independence assay, xenograft tumor formation in athymic mice Cancer research High 7627970
1996 Retroviral overexpression of MZF1 in IL-3-dependent FDCP.1 cells inhibits apoptosis upon IL-3 withdrawal and confers tumorigenic potential (tumor formation in congenic mice), indicating MZF1 promotes cell survival. Retroviral transduction, apoptosis assay upon cytokine withdrawal, syngeneic tumor formation assay Leukemia Medium 8667641
1998 MZF1 overexpression in HL-60 cells delays retinoic acid-induced differentiation and apoptosis and is associated with sustained Bcl-2 expression, suggesting MZF1 promotes cell proliferation and survival partly through Bcl-2. Retroviral transduction of HL-60 cells, cell-cycle analysis, morphologic differentiation scoring, TUNEL/DNA fragmentation assay, Western blot for Bcl-2, surface marker analysis Leukemia Medium 9593266
2000 The SCAN box (LeR domain) present in the MZF1B isoform mediates protein–protein interactions: it is required for heterodimerization with the novel SCAN-related protein RAZ1 (identified by bone marrow cDNA library screen) and for MZF1B homodimerization, as demonstrated by co-immunoprecipitation and yeast two-hybrid analyses. Bone marrow cDNA library two-hybrid screen, co-immunoprecipitation, yeast two-hybrid with truncation constructs, in vitro self-association assay The Journal of biological chemistry High 10777584
2001 Targeted inactivation of Mzf1 in mice produces lethal myeloid neoplasias (chloroma-like infiltrations of the liver) and markedly increases autonomous hematopoietic progenitor proliferation and long-term hematopoiesis, establishing Mzf1 as a tumor/growth suppressor in the hematopoietic compartment. Gene targeting (Mzf1 knockout mice), histopathology, hematopoietic colony assays, long-term culture-initiating cell assays Genes & development High 11445537
2005 MZF1 binds the GA-rich core of the human N-cadherin promoter (EMSA with osteoblast nuclear extracts, competition and supershift) and, together with Sp1, activates N-cadherin transcription in osteoblasts; Sp1 and MZF1 overexpression increases N-cadherin mRNA and protein. EMSA (including competition and supershift), deletion/mutation promoter-reporter analysis, co-transfection overexpression, RT-PCR Experimental cell research Medium 15541732
2005 NF-Y bound at CCAAT motifs in the ERV-9 LTR enhancer recruits MZF1 (and GATA-2) through protein–protein interactions to assemble an active enhancer complex (NF-Y/MZF1/GATA-2); NF-Y binding stabilizes MZF1 binding to neighboring GTGGGGA sites; mutation of the CCAAT motif abolishes enhancer activity and silences downstream gene transcription. EMSA, protein–protein interaction binding hierarchy assays (pull-down), chromatin analysis (DNase I sensitivity), stable plasmid integration reporter assay with site-directed mutations in K562 cells The Journal of biological chemistry Medium 16105833
2005 MZF1 binds PKCα promoter elements in hepatocellular carcinoma cells, and antisense MZF1 oligonucleotides reduce PKCα mRNA, DNA-binding activity at the PKCα promoter, and decrease cell proliferation, migration, and invasion, placing MZF1 upstream of PKCα expression. Antisense oligonucleotide knockdown, RT-PCR, EMSA (DNA binding to PKCα promoter), cell proliferation/migration/invasion assays Biochemical and biophysical research communications Medium 16297876
2005 MZF-1 interacts with LDOC1 (a leucine-zipper protein) and enhances LDOC1-induced apoptosis; LDOC1 overexpression causes phosphatidylserine externalization and mitochondrial membrane potential loss leading to caspase-3-dependent and independent apoptosis. Co-immunoprecipitation (identification of MZF-1/LDOC1 interaction), overexpression assays, flow cytometry (apoptosis), mitochondrial membrane potential assay FEBS letters Medium 15670815
2006 The MZF1 SCAN domain forms a domain-swapped homodimer (Kd ~600 nM) determined by NMR spectroscopy, with the dimer interface centered on helix 3 of each monomer; GST pull-down confirmed self-association; this structure provides the molecular basis for SCAN-domain-mediated protein–protein interactions in this subfamily of zinc-finger transcription factors. NMR structure determination, GST pull-down self-association assay, tryptophan fluorescence polarization (Kd measurement), comprehensive sequence analysis Journal of molecular biology High 16950398
2006 MZF1 represses ERCC1 promoter transcription: MZF1 N-terminal zinc fingers bind a MZF1-like site in the ERCC1 promoter (EMSA), MZF1 overexpression represses ERCC1 promoter-CAT activity, and cisplatin treatment decreases MZF1 mRNA, suggesting MZF1 normally represses ERCC1 and its loss upon cisplatin exposure allows ERCC1 upregulation. EMSA with MZF1 ZN1-4 consensus oligonucleotides, CAT reporter co-transfection assay, qPCR Biochemical pharmacology Medium 16426580
2007 MZF1 and Sp1/Sp3 bind the proximal PADI1 promoter in vivo (ChIP assay), and siRNA knockdown of MZF1 reduces PADI1 expression in keratinocytes; mutation of MZF1- or Sp1-binding sites markedly reduces PADI1 promoter activity, establishing MZF1 as a direct transcriptional activator of PADI1. Chromatin immunoprecipitation (ChIP), luciferase reporter assay with deletion/mutation constructs, siRNA knockdown, qRT-PCR The Journal of investigative dermatology High 17851584
2009 MZF-1 binds a cis-element at -785/-745 in the FGF-2 promoter (identified by promoter deletion screening) and mediates apomorphine-stimulated FGF-2 transcription in astrocytes; MZF-1 plasmid overexpression increases FGF-2 protein in HeLa cells and primary astrocytes, while MZF-1-specific siRNA reduces FGF-2 promoter activity. Promoter deletion/reporter assay, MZF-1 overexpression and siRNA knockdown, FGF-2 protein measurement Journal of neurochemistry Medium 19196427
2012 MZF1 binds the cis-element 'TGGGGA' in the p55PIK (PI3K regulatory subunit) promoter (ChIP assay), and MZF1 overexpression increases while MZF1 silencing decreases p55PIK promoter activity, p55PIK expression, and colorectal cancer cell proliferation. ChIP assay, promoter-luciferase reporter assay, MZF1 overexpression and siRNA knockdown, cell proliferation assay BioMed research international Medium 23509792
2014 MZF1 acts as a transcriptional activator of the ferroportin (FPN) gene; reduced MZF1 expression in prostate tumors leads to decreased FPN, increased intracellular iron retention, and enhanced tumor cell growth. AP4 and c-Myb jointly activate MZF1 transcription, while miR-492 directly binds the MZF1 3'UTR to suppress MZF1 expression. MZF1 knockdown/overexpression, FPN promoter-reporter assay, iron assay, cell growth assay, miR-492 3'UTR reporter assay, quantitative RT-PCR/Western blot Oncogene Medium 25284586
2014 Tumor-derived osteopontin (OPN) induces integrin-dependent MZF1 expression in mesenchymal stem cells, which is required for TGF-β1 production and MSC-to-cancer-associated-fibroblast (CAF) transformation; MZF1 knockdown abolishes OPN-induced TGF-β1 expression and CAF phenotype acquisition. In vitro MSC/cancer cell co-culture, OPN treatment, siRNA knockdown of MZF1, TGF-β1 ELISA, CAF marker analysis, xenotransplant mouse model Oncogene Medium 25531323
2014 Wild-type LKB1 loss increases MZF1 expression, and MZF1 directly transcriptionally upregulates c-MYC; the MZF1/c-MYC axis drives soft-agar growth, migration and invasion in lung adenocarcinoma cells; MYC inhibitors suppress LKB1-loss-induced invasiveness. LKB1 knockdown/overexpression, MZF1 promoter-reporter assay, ChIP, soft-agar colony formation, migration/invasion assays, MYC inhibitor treatment Oncogene Medium 24793789
2014 MZF1 binds and transactivates the FOXM1 promoter via the MZF1/NKX2-1 axis in HPV E6-positive cancer cells; E6-mediated upregulation of NKX2-1 induces MZF1, which drives FOXM1 expression and consequent Wnt/β-catenin activation, soft-agar growth, invasiveness, and stemness. siRNA knockdown, luciferase reporter assay, nude mouse metastasis model, FOXM1 inhibitor treatment, ChIP Neoplasia Medium 25425970
2015 MZF1 and Ik-1 bind specific sites in the IGF-IR gene promoter (ChIP assay), suppress IGF-IR promoter activity (luciferase assay), and forced MZF1 expression in NPM-ALK+ T-cell lymphoma cells decreases IGF-IR mRNA and protein, phospho-IGF-IR, IRS-1, AKT and NPM-ALK phosphorylation, and reduces cell viability, proliferation, migration, and anchorage-independent growth. ChIP assay, luciferase reporter assay, forced MZF1 expression, Western blot for downstream signaling, cell viability/proliferation/migration/colony assays Molecular cancer Medium 25884514
2015 MZF1 directly binds and activates the CTGF (CCN2) and NOV (CCN3) gene promoters in hematopoietic cells; calcitriol and vitamin A upregulate MZF1, which in turn induces CTGF and NOV expression; MZF1 shRNA knockdown reduces CTGF and NOV levels. MZF1-promoter interaction assay, MZF1 overexpression/knockdown, RT-PCR/Western blot, calcitriol/vitamin A stimulation Journal of cellular physiology Medium 25899830
2015 MZF1 directly binds the SMAD4 core promoter and stimulates SMAD4 transcriptional activity; MZF1 expression promotes SMAD4 levels and suppresses migration of gastric adenocarcinoma cells. Promoter-reporter assay, EMSA, MZF1 overexpression, migration assay International journal of oncology Medium 27922669
2015 MZF1 directly binds the GAPDH promoter and upregulation of MZF1 by calcitriol induces GAPDH expression in HS-5 stromal fibroblasts; shRNA knockdown of MZF1 reduces GAPDH expression. Promoter binding assay, MZF1 knockdown (shRNA), calcitriol stimulation, Western blot/RT-PCR Biochemical and biophysical research communications Medium 25065746
2015 MZF1 forms a direct physical complex with Elk-1: Elk-1 binds the N-terminal acidic region of MZF1, MZF1 binds the C-terminal region of Elk-1; the MZF1/Elk-1 heterodimer binds the PKCα promoter to activate PKCα transcription in hepatocellular carcinoma cells; disruption of MZF1/Elk-1 dimerization reduces PKCα expression, and cell proliferation, migration, invasion, and tumorigenicity. Co-immunoprecipitation, ChIP, Re-ChIP, luciferase reporter assay with DNA-binding-deficient mutants, cell functional assays PloS one High 26010542
2016 The acidic domain (residues 60–72) of MZF1 and the heparin-binding domain (residues 145–157) of Elk-1 constitute the heterodimerization interface; peptides from either domain block MZF1/Elk-1 complex formation, reduce PKCα promoter binding (DNA-binding activity), and decrease PKCα expression, cell migration, tumorigenicity, and EMT potential in triple-negative breast cancer cells. Peptide competition assay, co-immunoprecipitation, ChIP, luciferase reporter assay, cell migration/invasion/tumorigenicity assays Oncotarget Medium 27542222
2016 The MZF1 SCAN domain adopts a conformational ensemble (validated by NMR experimental data) that mediates protein–protein interactions; cancer-associated missense substitutions in the SCAN domain perturb its interaction network as revealed by integrated proteomics, RNAseq, and molecular dynamics simulations. NMR cross-validation, molecular dynamics simulations, high-throughput proteomics and RNASeq data analysis, computational network analysis Frontiers in molecular biosciences Medium 28018905
2017 MZF1 directly binds MZF1 consensus sites within the first intron (CpG-rich region) of the PRAME gene and activates PRAME transcription; DNA demethylation (5-azaC treatment) enhances MZF1 binding and further increases PRAME expression; MZF1, like PRAME, promotes colony-forming ability in melanoma cells. ChIP, luciferase reporter assay, 5-azaC treatment, EMSA, MZF1 overexpression, colony formation assay Cancer letters Medium 28634046
2017 TGF-β1-activated ERK1/2 signaling induces MZF1, which binds the CK17 promoter and activates CK17 transcription; CK17 (not EMT markers) mediates acquisition of cancer stem cell properties and lymphatic metastasis in cervical cancer; ERK1/2 inhibitors block TGF-β1-induced MZF1 and CK17 upregulation. Computational binding site prediction validated by ChIP, promoter-reporter assay, ERK1/2 inhibitor treatment, siRNA knockdown, in vivo lymphatic metastasis model The FEBS journal Medium 28703907
2018 FTO (m6A demethylase) enhances MZF1 mRNA stability by reducing m6A methylation of MZF1 mRNA; FTO knockdown reduces MZF1 expression (whereas catalytic mutant FTO does not rescue), and MZF1 mediates FTO's pro-tumorigenic functions in lung squamous cell carcinoma. FTO knockdown/overexpression (WT and catalytic mutant), RT-PCR/Western blot for MZF1, mRNA stability assay, cell proliferation/invasion/apoptosis assays Biochemical and biophysical research communications Medium 29842885
2018 CHIP/STUB1 ubiquitin ligase negatively regulates MZF1 DNA-binding activity in the nucleus; loss of nuclear CHIP in breast cancer unleashes MZF1-driven cathepsin B/L (CTSB/L) expression, promoting tumor cell invasion and matrix degradation; ectopic CHIP expression suppresses MZF1 activity and in vivo xenograft growth. Unbiased nuclear transcription factor screen, ectopic CHIP expression, CTSB/L expression analysis, in vitro invasion/matrix degradation assays, in vivo xenograft assay Cancer research Medium 29510992
2018 CK2 directly phosphorylates MZF1 at serine 27, which stabilizes MZF1 protein; stabilized MZF1 binds the N-cadherin promoter (ChIP) and activates N-cadherin transcription; MZF1 knockdown downregulates N-cadherin, reverts cancer cells from mesenchymal to epithelial morphology, and reduces motility and invasiveness. N-cadherin promoter analysis, ChIP, co-immunoprecipitation (MZF1–CK2 interaction), phosphorylation assay (serine 27), MZF1 knockdown, morphology/motility/invasion assays Oncogenesis High 29540671
2019 The FBXO28–TRAF6 E3 ligase complex binds ERK5, promotes ERK5 K63-ubiquitination and phosphorylation; activated ERK5 drives MZF1 expression, and MZF1 directly binds the RGC-32 promoter to upregulate RGC-32, ultimately mediating sublytic C5b-9-induced mesangial cell proliferation and ECM expansion in glomerulonephritis. Western blot, co-immunoprecipitation (FBXO28–TRAF6–ERK5 complex), ubiquitination assay, MZF1 promoter-binding analysis, siRNA knockdown of each component, in vivo Thy-1 nephritis rat model Journal of cellular and molecular medicine Medium 31184423
2019 MZF1 binds the TRPV1 promoter in dorsal root ganglion (DRG) neurons and regulates TRPV1 expression; DRG microinjection of MZF1 overexpression virus increases TRPV1 and induces mechanical allodynia/thermal hyperalgesia, while MZF1 siRNA reduces CCI-induced TRPV1 upregulation and alleviates neuropathic pain behaviors. DRG microinjection of rAAV5-MZF1 or MZF1 siRNA, behavioral pain assays (PWT, PWL), Western blot/immunofluorescence for TRPV1 Neural plasticity Medium 31582966
2019 MZF1 promotes HK2 and PGK1 expression to drive aerobic glycolysis in neuroblastoma. YY1 transcription factor transactivates MZF1 transcription; a 21-amino-acid peptide (MZF1-uPEP) encoded by the upstream ORF of MZF1 binds the zinc finger domain of YY1, represses YY1 transactivation, and thereby reduces MZF1, HK2, and PGK1 expression and inhibits glycolysis and tumor progression. Dual-luciferase assay, ChIP, co-immunoprecipitation, mass spectrometry, peptide pull-down assay, seahorse extracellular flux, soft agar, Matrigel invasion, nude mice xenograft Theranostics High 32042322
2019 MZF1 acts as a transcription factor for ALDH18A1 and PYCR1, promoting proline synthesis in neuroblastoma; MZF1-AS1 lncRNA binds PARP1 to facilitate its interaction with E2F1, resulting in E2F1 transactivation of MZF1 and downstream oncogenic genes; a small peptide blocking MZF1-AS1–PARP1 interaction suppresses proline synthesis and NB progression. Dual-luciferase assay, ChIP, co-immunoprecipitation, peptide/RIP pulldown, amino acid profiling, lentiviral MZF1-AS1 shRNA, in vivo tumor assays Advanced science Medium 31592410
2019 MZF1 binds the Mtor promoter at the TGGGGA cis-element near the transcription start site and down-regulates Mtor expression; a BALB mouse-specific T at the -6 position creates the consensus MZF1 binding site, explaining strain-specific differences in Mtor promoter activity; MZF1 overexpression reduces and Mzf1 knockdown increases Mtor expression in fibroblasts and plasmacytoma cells. EMSA, DNA pulldown, ChIP-PCR, luciferase reporter assay with allelic variants, MZF1 overexpression/knockdown in cell lines The Journal of biological chemistry High 31548308
2020 Linc01060 (a lncRNA from hypoxic glioma stem cell exosomes) directly interacts with MZF1 protein and enhances its stability; Linc01060 facilitates nuclear translocation of MZF1 and promotes MZF1-mediated c-Myc transcriptional activity; c-Myc then increases HIF1α accumulation post-transcriptionally, which feeds back to activate Linc01060 transcription. RNA immunoprecipitation (RIP), co-immunoprecipitation, nuclear fractionation, dual-luciferase, ChIP, overexpression/knockdown assays Cancer research Medium 33158815
2021 MZF1 recruits chromodomain helicase DNA binding protein 7 (CHD7) to the p16INK4A (CDKN2A) promoter to mediate oncogenic Ras-induced p16INK4A transcription and cellular senescence in primary human cells; MZF1 expression is induced by oncogenic Ras through the c-Jun and Ets1 transcription factors activated by the Ras-Raf-1-MEK-ERK signaling cascade. ChIP, co-immunoprecipitation (MZF1–CHD7), MZF1 knockdown/overexpression, p16INK4A promoter-reporter assay, senescence assays (SA-β-gal), oncogenic Ras expression, pathway inhibitor treatments Oncogene High 34773072
2021 GSK3β mediates ubiquitination and degradation of the m6A demethylase FTO, thereby increasing m6A methylation of MZF1 mRNA and reducing MZF1 expression, which in turn decreases c-Myc expression and suppresses colorectal cancer cell proliferation; overexpressing c-Myc reverses GSK3β-mediated tumor suppression in vivo. Ubiquitination assay, m6A MeRIP, protein stability assay, transfection of overexpression/interference plasmids, in vivo tumor model Journal of cellular and molecular medicine Medium 33533172
2021 Irradiation increases MZF1 expression in alveolar epithelial cells; MZF1 binds the miR-541-5p primary precursor promoter and represses miR-541-5p transcription; reduced miR-541-5p releases its target Slug, promoting EMT and radiation-induced pulmonary fibrosis; ectopic miR-541-5p expression mitigates RIPF in mice. Luciferase reporter assay, ChIP (MZF1 binding to miR-541-5p promoter), overexpression/knockdown of MZF1 and miR-541-5p, in vivo RIPF mouse model, EMT marker analysis International journal of molecular sciences Medium 34768749
2022 MZF1 cooperates with SETD8 (lysine methyltransferase) to regulate WNT5A promoter transcription in glomerular endothelial cells: MZF1 and SETD8 co-occupy the WNT5A promoter (ChIP), physically interact (Co-IP), and under high-glucose conditions MZF1 and SETD8 mutually inhibit each other while together activating WNT5A, leading to NF-κB pathway activation and endothelial inflammation. ChIP, co-immunoprecipitation, dual-luciferase assay, siRNA/overexpression of MZF1 and SETD8, in vivo DN rat model, Western blot for p-p65/inflammatory markers Cellular & molecular biology letters Medium 35350980
2022 MZF1 binds the SIRT6 promoter and regulates SIRT6 expression; SIRT6 inhibits the Warburg effect by regulating glycolysis genes (SLC2A2, SLC2A4, PKM2); the MZF1-SIRT6 complex is demonstrated by ChIP-qPCR; mitoAMPK acts upstream of the MZF1-SIRT6 axis. ChIP-qPCR (MZF1–SIRT6 promoter interaction), Western blot, qPCR, CCK-8, immunohistochemistry, glycolysis gene expression analysis Journal of cellular and molecular medicine Low 39224032
2023 MZF1 binds and represses the SLC1A5 (ASCT2) promoter; the lncRNA SLC1A5-AS directly binds MZF1 protein (biotin-labeled probe pulldown), sequestering it from the promoter and thereby de-repressing ASCT2 to enhance glutamine uptake and HCC progression. Biotin-labeled RNA probe pulldown/Western blot (SLC1A5-AS–MZF1 interaction), ChIP, dual-luciferase reporter assay, overexpression/knockdown, glutamine uptake assay, in vitro and in vivo functional assays Discovery medicine Medium 38058065
2023 UHRF1/DNMT1-mediated hypermethylation of an intragenic CpG island in PRSS3 prevents MZF1 binding to regulate PRSS3 isoform transcription; when iCpGI is demethylated (by diallyl trisulfide + 5-azaC), MZF1 specifically binds to upregulate tumor-suppressive PRSS3-V3 expression. DNMT1/UHRF1 complex assay, bisulfite sequencing, MZF1 ChIP on iCpGI, luciferase reporter assay, pharmacologic demethylation, isoform-specific RT-PCR Acta pharmaceutica Sinica. B Medium 37250150
2023 MZF1 accelerates PD-L1 ubiquitination by binding to the CDK4 activation site; CDK4 directly binds MZF1 (co-immunoprecipitation) leading to increased MZF1 expression; ectopic MZF1 expression impairs T-cell recruitment into tumors and confers resistance to anti-PD-L1 immunotherapy in hepatocellular carcinoma. Co-immunoprecipitation (CDK4–MZF1 complex), ubiquitination assay, proteome analysis, protein degradation assays, orthotopic and hydrodynamic HCC mouse models, T-cell infiltration analysis JHEP reports Medium 38074509
2023 MZF1 is the transcription factor that activates CLDND1 expression; the miR-199a-3p/FTO/MZF1 axis regulates NSCLC: miR-199a-3p suppresses FTO, enhancing m6A modification of MZF1 mRNA (confirmed by MeRIP and CLIP) and reducing MZF1, which decreases CLDND1 and inhibits NSCLC cell malignancy. Methylated RNA immunoprecipitation (MeRIP), CLIP (photoactivatable ribonucleoside-enhanced CLIP for FTO–MZF1 mRNA binding), dual-luciferase assay (miR-199a-3p targeting FTO; MZF1 activating CLDND1), MZF1 knockdown, cell proliferation/invasion/migration/apoptosis assays Molecular medicine reports Medium 41201047
2025 MZF1 forms discrete intranuclear oligomeric structures termed MZF1 nuclear bodies (MZF1-NBs), distinct from but associated with PML-NBs; MZF1 is SUMOylated at SUMO1 in PC-3 cells, enabling interaction with SUMO-interaction motif (SIM)-containing proteins; interactome analysis of MZF1-NBs identified cofactors involved in stress response (TPR, UBAP2L), protein folding (CALR, ANKRD40), post-translational modification (TRIM33, CAMK2D, CAMK2G), and RNA binding (ALURBP, CPSF5). Live-cell imaging (nuclear body morphology), proteomic interactome analysis, co-immunoprecipitation, SUMO1 modification assay Biochemical and biophysical research communications Medium 39954358
2025 NSUN2-mediated m5C modification of MZF1 mRNA is required for its recognition and stabilization by the m5C reader protein ALYREF; ALYREF knockdown reduces MZF1 and HTRA1 expression, alleviates myocardial hypertrophy, fibrosis, and atrial fibrillation inducibility in an ISO-induced heart failure mouse model. MeRIP-qPCR for m5C on MZF1 mRNA, RIP-qPCR (ALYREF–MZF1 mRNA interaction), actinomycin D mRNA stability assay, ChIP (MZF1 on HTRA1 promoter), dual-luciferase reporter, in vivo HF mouse model with ALYREF knockdown Cellular and molecular life sciences Medium 42249105

Source papers

Stage 0 corpus · 78 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression. Biochemical and biophysical research communications 200 29842885
2014 Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene 191 25531323
1994 Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core. Molecular and cellular biology 174 8114711
1991 A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. The Journal of biological chemistry 167 1860835
2001 Mzf1 controls cell proliferation and tumorigenesis. Genes & development 112 11445537
2020 Hypoxic Glioma Stem Cell-Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZF1/c-Myc/HIF1α Axis. Cancer research 106 33158815
1995 Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Molecular and cellular biology 105 7565760
1995 The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 96 7579328
1996 Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1. Current topics in microbiology and immunology 84 8585946
1991 Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro. The Journal of experimental medicine 79 1719120
2014 The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene 62 24793789
1995 Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic. Cancer research 60 7627970
2005 Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Experimental cell research 57 15541732
2014 Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene 54 25284586
2005 The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2. The Journal of biological chemistry 50 16105833
2005 PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochemical and biophysical research communications 48 16297876
2017 TGF-β1-induced CK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway. The FEBS journal 46 28703907
2000 Identification of a novel SCAN box-related protein that interacts with MZF1B. The leucine-rich SCAN box mediates hetero- and homoprotein associations. The Journal of biological chemistry 46 10777584
1998 The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells. Leukemia 46 9593266
2014 Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis. Neoplasia (New York, N.Y.) 44 25425970
2020 Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression. Theranostics 42 32042322
2018 Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer research 40 29510992
2019 Therapeutic Targeting of MZF1-AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 38 31592410
2012 p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation. BioMed research international 38 23509792
2005 LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS letters 38 15670815
2020 Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion. Cells 37 31963147
2017 Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells. Cancer letters 36 28634046
2021 Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis. Journal of cellular and molecular medicine 35 33533172
2006 MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochemical pharmacology 33 16426580
2009 Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures. Journal of neurochemistry 29 19196427
2007 Crucial roles of MZF1 and Sp1 in the transcriptional regulation of the peptidylarginine deiminase type I gene (PADI1) in human keratinocytes. The Journal of investigative dermatology 29 17851584
2016 The Mutational Landscape of the Oncogenic MZF1 SCAN Domain in Cancer. Frontiers in molecular biosciences 28 28018905
2021 Irradiation Activates MZF1 to Inhibit miR-541-5p Expression and Promote Epithelial-Mesenchymal Transition (EMT) in Radiation-Induced Pulmonary Fibrosis (RIPF) by Upregulating Slug. International journal of molecular sciences 25 34768749
2007 Suppression of tumorigenicity of human hepatocellular carcinoma cells by antisense oligonucleotide MZF-1. The Chinese journal of physiology 25 17593797
1995 Isolation and functional characterization of the human gene encoding the myeloid zinc finger protein MZF-1. Biochemistry 25 8845378
1996 Forced over-expression of the myeloid zinc finger gene MZF-1 inhibits apoptosis and promotes oncogenesis in interleukin-3-dependent FDCP.1 cells. Leukemia 24 8667641
2015 The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma. Molecular cancer 21 25884514
2015 MZF-1/Elk-1 Complex Binds to Protein Kinase Cα Promoter and Is Involved in Hepatocellular Carcinoma. PloS one 21 26010542
2023 UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer. Acta pharmaceutica Sinica. B 20 37250150
2018 Phosphorylation-dependent stabilization of MZF1 upregulates N-cadherin expression during protein kinase CK2-mediated epithelial-mesenchymal transition. Oncogenesis 20 29540671
2006 Structure of the SCAN domain from the tumor suppressor protein MZF1. Journal of molecular biology 20 16950398
2023 Design and In Silico Validation of a Novel MZF-1-Based Multi-Epitope Vaccine to Combat Metastatic Triple Negative Breast Cancer. Vaccines 16 36992161
2021 MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A. Oncogene 16 34773072
2022 SETD8 cooperates with MZF1 to participate in hyperglycemia-induced endothelial inflammation via elevation of WNT5A levels in diabetic nephropathy. Cellular & molecular biology letters 15 35350980
2019 Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex. Journal of cellular and molecular medicine 15 31184423
2016 MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells. Oncotarget 15 27542222
2016 Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells. International journal of oncology 15 27922669
2023 Asiatic acid exhibits antimetastatic activity in human prostate cancer cells by modulating the MZF-1/Elk-1/Snail signaling axis. European journal of pharmacology 12 37209940
2019 MZF1 in the Dorsal Root Ganglia Contributes to the Development and Maintenance of Neuropathic Pain via Regulation of TRPV1. Neural plasticity 12 31582966
2023 LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma. Discovery medicine 11 38058065
2014 Myeloid zinc finger 1 (Mzf1) differentially modulates murine cardiogenesis by interacting with an Nkx2.5 cardiac enhancer. PloS one 11 25436607
2023 MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma. JHEP reports : innovation in hepatology 10 38074509
2019 Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells. Anticancer research 10 31366500
2019 The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility. The Journal of biological chemistry 10 31548308
2012 Expression of protein kinase C α and the MZF-1 and Elk-1 transcription factors in human breast cancer cells. The Chinese journal of physiology 10 22242952
1996 The location of MZF-1 at the telomere of human chromosome 19q makes it vulnerable to degeneration in aging cells. Leukemia research 10 8637224
2022 Inhibition of MZF1/c-MYC Axis by Cantharidin Impairs Cell Proliferation in Glioblastoma. International journal of molecular sciences 9 36499054
2005 MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene. Experimental cell research 9 15893750
2021 MZF1 alleviates oxidative stress and apoptosis induced by rotenone in SH-SY5Y cells by promoting RBM3 transcription. The Journal of toxicological sciences 8 34602532
2014 The glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) is regulated by myeloid zinc finger 1 (MZF-1) and is induced by calcitriol. Biochemical and biophysical research communications 8 25065746
2015 Myeloid Zinc Finger 1 (MZF-1) Regulates Expression of the CCN2/CTGF and CCN3/NOV Genes in the Hematopoietic Compartment. Journal of cellular physiology 7 25899830
2012 Expression of protein kinase Cα and the MZF-1 and elk-1 transcription factors in human bladder transitional cell carcinoma cells. The Chinese journal of physiology 7 22559731
2024 Amelioration of nitroglycerin-induced migraine in mice via Wuzhuyu decoction: Inhibition of the MZF1/PGK1 pathway and activation of NRF2 antioxidant response. Journal of ethnopharmacology 6 38373662
2022 MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44. Journal of immunology research 6 35669102
2022 Axl Expression in Renal Mesangial Cells Is Regulated by Sp1, Ap1, MZF1, and Ep300, and the IL-6/miR-34a Pathway. Cells 6 35740998
2020 Cigarette smoke modulates binding of the transcription factor MZF1 to the VEGF promoter and regulates VEGF expression in dependence of genetic variation SNP 405. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 6 32449233
2024 MitoAMPK inhibits the Warburg effect by MZF1-SIRT6 with glycosis related genes in NSCLC. Journal of cellular and molecular medicine 5 39224032
2013 Haplotype of single nucleotide polymorphisms in exon 6 of the MZF-1 gene and Alzheimer's disease. Journal of Alzheimer's disease : JAD 4 23241556
2024 Solamargine acts as an antiviral by interacting to MZF1 and targeting the core promoter of the hepatitis B virus gene. Aging 2 39133152
2025 Discovery of myeloid zinc finger (MZF) 1 nuclear bodies. Biochemical and biophysical research communications 1 39954358
2025 PRAME-AS lncRNA, regulated by MZF1, modulates PRAME expression and cell stemness. PloS one 1 40961095
2025 FTO-Mediated m6A Demethylation of MZF1 Regulates DECR1 to Promote Fatty Acid Oxidation and Exacerbate Myocardial Ischemia/Reperfusion Injury : FTO-Mediated m6A Demethylation of MZF1 Enhances Fatty Acid Oxidation and Aggravates Myocardial I/R Injury. Biochemical genetics 1 41003915
2026 ALYREF stabilizes MZF1 via m5C modification to exacerbate cardiac remodeling and atrial fibrillation in heart failure. Cellular and molecular life sciences : CMLS 0 42249105
2025 MicroRNA‑199a‑3p suppresses non‑small cell lung cancer progression by targeting FTO to enhance m6A‑mediated downregulation of MZF1 and its transcriptional activation of CLDND1. Molecular medicine reports 0 41201047
2025 MZF1-AS1/NSUN2 promotes the peritoneal metastasis of gastric cancer by enhancing the stability of RAB13 mRNA. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 0 41343127
2020 RETRACTED: MZF1 regulates α-globin gene transcription via long-range interactions in erythroid differentiation. Blood cells, molecules & diseases 0 33352376
2019 [Effects of Transcription Factor MZF-1 on Transcriptive Regulation of Acute Monocytic Leukemia-related Gene MLAA-34]. Zhongguo shi yan xue ye xue za zhi 0 31607299
2019 Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1. International journal of clinical and experimental pathology 0 31934032

Missed literature

Know a paper Affinage missed for MZF1? Flag it for the maintainers and the community.

No submissions yet.